Wanda DePinto

432 total citations
8 papers, 268 citations indexed

About

Wanda DePinto is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Wanda DePinto has authored 8 papers receiving a total of 268 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Wanda DePinto's work include Cancer-related Molecular Pathways (7 papers), Advanced Breast Cancer Therapies (3 papers) and Cancer therapeutics and mechanisms (2 papers). Wanda DePinto is often cited by papers focused on Cancer-related Molecular Pathways (7 papers), Advanced Breast Cancer Therapies (3 papers) and Cancer therapeutics and mechanisms (2 papers). Wanda DePinto collaborates with scholars based in United States, Australia and Switzerland. Wanda DePinto's co-authors include Kin‐Chun Luk, Yingsi Chen, U. Kammlott, Mary Ellen Simcox, Xuefeng Yin, Kathryn Packman, Brian Gabrielli, Melissa Smith, Rachid Hamid and Mark DeMario and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Wanda DePinto

8 papers receiving 258 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wanda DePinto United States	7	139	135	75	64	59	8	268
Zhipei Wu China	6	126 0.9×	113 0.8×	64 0.9×	79 1.2×	48 0.8×	7	281
Sebastian H. B. Kroll United Kingdom	7	194 1.4×	205 1.5×	117 1.6×	50 0.8×	58 1.0×	7	348
Christopher Meades United Kingdom	6	142 1.0×	182 1.3×	58 0.8×	119 1.9×	95 1.6×	8	347
Fulvia Roletto Italy	9	87 0.6×	174 1.3×	38 0.5×	72 1.1×	43 0.7×	12	303
Scott A. Watkins United States	9	117 0.8×	192 1.4×	47 0.6×	177 2.8×	36 0.6×	11	404
Takumitsu Machida Japan	8	143 1.0×	192 1.4×	47 0.6×	141 2.2×	68 1.2×	10	361
Nobuhiko Kawanishi Japan	9	158 1.1×	182 1.3×	36 0.5×	146 2.3×	107 1.8×	10	367
Lynsey Fazal United Kingdom	8	96 0.7×	216 1.6×	23 0.3×	66 1.0×	83 1.4×	16	330
Jacob I. Contreras United States	10	195 1.4×	344 2.5×	85 1.1×	124 1.9×	61 1.0×	12	536
Kin‐Chun Luk United States	10	113 0.8×	202 1.5×	26 0.3×	125 2.0×	40 0.7×	15	342

Countries citing papers authored by Wanda DePinto

Since Specialization

Citations

This map shows the geographic impact of Wanda DePinto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wanda DePinto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wanda DePinto more than expected).

Fields of papers citing papers by Wanda DePinto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wanda DePinto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wanda DePinto. The network helps show where Wanda DePinto may publish in the future.

Co-authorship network of co-authors of Wanda DePinto

This figure shows the co-authorship network connecting the top 25 collaborators of Wanda DePinto. A scholar is included among the top collaborators of Wanda DePinto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wanda DePinto. Wanda DePinto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Berkofsky‐Fessler, Windy, Paul Delmar, Juliette Molnos, et al.. (2009). Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients. Molecular Cancer Therapeutics. 8(9). 2517–2525. 18 indexed citations

Diab, Sarah, S. Gail Eckhardt, Antoinette R. Tan, et al.. (2007). A phase I study of R547, a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases (CDKs). Journal of Clinical Oncology. 25(18_suppl). 3528–3528. 26 indexed citations

Burgess, Andrew, et al.. (2006). Inhibition of S/G2 Phase CDK4 Reduces Mitotic Fidelity. Journal of Biological Chemistry. 281(15). 9987–9995. 29 indexed citations

DePinto, Wanda, Xin‐Jie Chu, Xuefeng Yin, et al.. (2006). In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Molecular Cancer Therapeutics. 5(11). 2644–2658. 88 indexed citations

Ding, Qingjie, Nan Jiang, Xin‐Jie Chu, et al.. (2005). Design, synthesis of 1,4-cyclohexyldiamine substituted diaminopyrimidines as selective inhibitors of CDK1, CDK2 and CDK4 and their in vitro and in vivo evaluation. Cancer Research. 65. 1045–1045. 1 indexed citations

Luk, Kin‐Chun, Mary Ellen Simcox, Karen Rowan, et al.. (2004). A new series of potent oxindole inhibitors of CDK2. Bioorganic & Medicinal Chemistry Letters. 14(4). 913–917. 41 indexed citations

Luk, Kin‐Chun, et al.. (2003). Synthesis of Potent Oxindole CDK2 Inhibitors. Bioorganic & Medicinal Chemistry. 11(8). 1873–1881. 40 indexed citations

Liu, Jinjun, Christine Lukacs, Yi Chen, et al.. (2003). 3,5,6-Trisubstituted naphthostyrils as CDK2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 13(15). 2465–2468. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact